Needham Reiterates Buy on Viridian Therapeutics, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a price target of $38.
October 28, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a Buy rating on Viridian Therapeutics and maintained a price target of $38, indicating confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $38 price target by a reputable analyst suggests a positive outlook for Viridian Therapeutics. This can boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100